Protek PAO operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Protek PAO with three other
pharmaceutical manufacturers in Europe:
sales of 4.18 billion Euro [US$4.96 billion]
of which 100%
Stada Arzneimittel AG
(2.14 billion Euro [US$2.54 billion]
of which 60%
was Generics), and
Lonza Group AG
based in Switzerland
(4.13 billion Swiss Francs [US$4.24 billion]
of which 54%
was Specialty Ingredients).
During the year ended December of 2016, sales at
Protek PAO were 241.48 billion Russian Rubles (US$4.23 billion).
increase of 23.6%
versus 2015, when the company's sales were 195.31 billion Russian Rubles.
This was the fifth consecutive year of sales increases at Protek PAO
(and since 2011, sales have increased a total of 126%).
Sales of Retail Sales saw an increase
32.2% in 2016, from
30.07 billion Russian Rubles to 39.76 billion Russian Rubles.
Not all segments of Protek PAO experienced an increase in sales in 2016:
sales of Production fell 6.4% to 5.90 billion Russian Rubles.
(However, this segment's sales were only a very small portion of the company's overall sales).